Gilead-Tubulis $5B Deal Gives STRO Stock A Boost — Here’s Why

• The Gilead-Tubulis deal is aimed at expanding Gilead’s ADC capabilities by adding Tubulis’s assets that include its lead asset TUB-040.
• According to Leerink analyst Andrew Berens, this acquisition serves as further validation of the antibody-drug conjugate space including Sutro Biopharma. 
• Leerink believes Sutro represents a similar set-up as Tubulis, although earlier in clinical development and technological validation.

Gilead Sciences, Inc. (GILD) said on Tuesday that it has entered into a definitive agreement to acquire a private German clinical-stage biotechnology company, Tubulis GmbH, a move that investment bank Leerink believes should be a tailwind for other antibody-drug conjugate (ADC) platform companies like Sutro Biopharma.

STRO shares rose 7% at the time of writing while GILD fell 1%.

Gilead-Tubulis Agreement Terms

Under the terms of the deal, Gilead will acquire all of the outstanding equity of Tubulis for $3.15 billion in upfront cash consideration, and up to $1.85 billion in contingent milestone payments.

The move is aimed at expanding Gilead’s Antibody-drug conjugates capabilities by adding Tubulis’s assets, including its lead asset TUB-040 which is in development to treat certain ovarian cancer and non-small cell lung cancer patients.

The transaction is expected to close in the second quarter of 2026, Gilead said.

ADCs are targeted biopharmaceutical cancer treatments that deliver potent cancer drugs directly to cancer cells while minimizing healthy tissue damage.

Leerink Weighs In

According to Leerink analyst Andrew Berens, this acquisition serves as further validation of the ADC space and should be a tailwind for other ADC platform companies ,including Sutro Biopharma (STRO), as well as Immunome (IMNM) and Zymeworks (ZYME). This deal underscores the strategic value of an ADC discovery platform anchored to a lead asset to large pharma, Berens said.

However, while there are a number of similarities between Tubulis' platform and portfolio and that of Sutro, it is possible the acquisition price may have been supported by potential expansion of the Tubulis chemistry and technology beyond oncology and into inflammation and virology, Leerink said, as per TheFly. Leerink believes Sutro represents a similar set-up, although earlier in clinical development and technological validation.

How Did Retail Traders React?

On Stocktwits, retail sentiment around GILD stock stayed within the ‘bearish’ territory over the past 24 hours, while message volume  stayed at ‘high’ levels.

Meanwhile, sentiment around STRO stock remained ‘bullish,’ coupled with ‘low’ message volume.

While GILD shares have risen 31% this year, STRO stock has nearly quadrupled. 

Read More: Novo Nordisk Launches Higher Dose Of Wegovy Injection Across US — Retail Thinks Stock Is ‘Terribly Undervalued’

For updates and corrections, email newsroom[at]stocktwits[dot]com.